热门资讯> 正文
Travere获得FDA全面批准肾脏药物Filspari
2024-09-06 18:45
- Travere Therapeutics (NASDAQ:TVTX) traded higher in the premarket on Friday after the U.S. Food and Drug Administration (FDA) granted full approval for its kidney disease drug, Filspari (sparsentan).
- The once-daily oral medication developed by Travere (TVTX) in partnership with Ligand Pharmaceuticals (NASDAQ:LGND) was granted the FDA’s accelerated approval in Feb. 2023 to reduce proteinuria in adults with IgA nephropathy, a rare progressive kidney disease.
- While accelerated approval was based on the surrogate marker of proteinuria, long-term confirmatory results from the company’s PROTECT study backed its full approval.
- “Full approval now enables physicians to confidently prescribe FILSPARI more broadly as a once-daily, oral, non-immunosuppressive treatment, that can provide superior preservation of kidney function and replace current standard of care,” said Travere (TVTX) CEO Eric Dube.
More on Ligand Pharmaceuticals, Travere Therapeutics, etc.
- Travere Therapeutics: Judgement Day Is Nigh For Sparsentan
- Ligand Pharmaceuticals Incorporated (LGND) Q2 2024 Earnings Call Transcript
- Ligand Pharmaceuticals Incorporated 2024 Q2 - Results - Earnings Call Presentation
- Roth MKM says Small-Cap Value reaches key technical support, lists 14 "bullish" stocks
- Ligand Pharmaceuticals reports mixed Q2 results; reaffirms FY24 outlook
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
